Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022

Christoph Friedli; Anke Salmen; Robert Hoepner; Lutz Achtnichts; Sandra Bigi; Tobias Derfuss; Claudio Gobbi; Nicole Kamber; Christian P. Kamm; Jens Kuhle; Patrice Lalive; Stefanie Müller; Athina Papadopoulou; Caroline Pot; Chiara Zecca; Andrew Chan

doi:10.3390/ctn7010002

Clinical and Translational Neuroscience (Dec 2022)

Specific Aspects of Immunotherapy for Multiple Sclerosis in Switzerland—A Structured Commentary, Update 2022

Christoph Friedli,
Anke Salmen,
Robert Hoepner,
Lutz Achtnichts,
Sandra Bigi,
Tobias Derfuss,
Claudio Gobbi,
Nicole Kamber,
Christian P. Kamm,
Jens Kuhle,
Patrice Lalive,
Stefanie Müller,
Athina Papadopoulou,
Caroline Pot,
Chiara Zecca,
Andrew Chan

Affiliations

Christoph Friedli: Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland
Anke Salmen: Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland
Robert Hoepner: Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland
Lutz Achtnichts: Department of Neurology, Aarau Cantonal Hospital, 5000 Aarau, Switzerland
Sandra Bigi: Institute of Social and Preventive Medicine, University of Bern, 3010 Bern, Switzerland
Tobias Derfuss: Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, 4031 Basel, Switzerland
Claudio Gobbi: Multiple Sclerosis Center, Neurocenter of Southern Switzerland, EOC, 6900 Lugano, Switzerland
Nicole Kamber: Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland
Christian P. Kamm: Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland
Jens Kuhle: Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, 4031 Basel, Switzerland
Patrice Lalive: Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospitals and Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland
Stefanie Müller: Department of Neurology, Cantonal Hospital St Gallen, 9000 St Gallen, Switzerland
Athina Papadopoulou: Neurologic Clinic and Policlinic and Research Center for Clinical Neuroimmunology and Neuroscience, Departments of Medicine, Biomedicine, and Clinical Research, University Hospital Basel, University of Basel, 4031 Basel, Switzerland
Caroline Pot: Service of Neurology, Department of Clinical Neurosciences, Lausanne University Hospital, University of Lausanne, 1011 Lausanne, Switzerland
Chiara Zecca: Multiple Sclerosis Center, Neurocenter of Southern Switzerland, EOC, 6900 Lugano, Switzerland
Andrew Chan: Department of Neurology, Inselspital, Bern University Hospital and University of Bern, 3010 Bern, Switzerland

DOI: https://doi.org/10.3390/ctn7010002
Journal volume & issue: Vol. 7, no. 1
p. 2

Abstract

Read online

Multiple sclerosis (MS), particularly relapsing MS (RMS), has become a treatable disease in recent decades, and immunotherapies are now able to influence long-term disease course. A wide range of disease-modifying drugs are available, which makes the choice of therapy in individual cases considerably more complex. Due to specific regulatory aspects (partly diverging approvals by Swissmedic compared to the European Medicines Agency (EMA), and an independent evaluation process for the Federal Office of Public Health (FOPH) specialities list (SL)), we issued a consensus recommendation regarding specific aspects of immunotherapy for MS in Switzerland in 2019. Here, we present revised recommendations with an update on newly approved drugs and new safety aspects, also in reference to the risk of COVID-19 infection and vaccination.

Published in Clinical and Translational Neuroscience

ISSN: 2514-183X (Online)
Publisher: MDPI AG
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Neurosciences. Biological psychiatry. Neuropsychiatry
Website: https://www.mdpi.com/journal/ctn

About the journal

Abstract

Keywords